RE:RE:RE:RE:To sum it up You may be right on that on the ahort point, as for CURA I see them as the US version of CGC in terms of strategy, they just have a bigger more complex market to work in. The jury is still out on both those companies, although CGC is not in control of their direction, as STZ is really behind all the decisions. CURA is big, but they are definitely feeling the wait of debt and cash burn and there is a large investor behind CURA who is feeling the pressure as well. My opinion, the tide has turned in the US and some changes are imminent, but it's a process. There are some very disciplined MSOs that will thrive, many will not. There.will be room made in the market for smaller players via social justice reform, and we will see some big winners emerge that will dominate the bulk of the US market. I'm thinking a top 2 or 3 will be the end game and or possibly merger with some whales.